Head-To-Head Survey: EnteroMedics (RSLS) vs. Its Rivals

EnteroMedics (NASDAQ: RSLS) is one of 76 publicly-traded companies in the “Advanced Medical Equipment & Technology” industry, but how does it weigh in compared to its peers? We will compare EnteroMedics to similar companies based on the strength of its institutional ownership, profitability, earnings, risk, dividends, valuation and analyst recommendations.

Institutional and Insider Ownership

0.6% of EnteroMedics shares are owned by institutional investors. Comparatively, 50.2% of shares of all “Advanced Medical Equipment & Technology” companies are owned by institutional investors. 32.5% of EnteroMedics shares are owned by company insiders. Comparatively, 18.4% of shares of all “Advanced Medical Equipment & Technology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares EnteroMedics and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
EnteroMedics $790,000.00 -$23.36 million -0.27
EnteroMedics Competitors $2.14 billion $229.91 million -29.32

EnteroMedics’ peers have higher revenue and earnings than EnteroMedics. EnteroMedics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

EnteroMedics has a beta of 3.09, suggesting that its share price is 209% more volatile than the S&P 500. Comparatively, EnteroMedics’ peers have a beta of 1.25, suggesting that their average share price is 25% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for EnteroMedics and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EnteroMedics 0 0 1 0 3.00
EnteroMedics Competitors 271 1867 3326 105 2.59

EnteroMedics currently has a consensus price target of $11.03, indicating a potential upside of 598.10%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 10.16%. Given EnteroMedics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe EnteroMedics is more favorable than its peers.

Profitability

This table compares EnteroMedics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
EnteroMedics -4,509.61% -104.23% -90.59%
EnteroMedics Competitors -153.35% -23.72% -8.87%

Summary

EnteroMedics peers beat EnteroMedics on 7 of the 12 factors compared.

About EnteroMedics

ReShape Lifesciences Inc., formerly EnteroMedics Inc., is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve. The Company’s initial product is the Maestro Rechargeable System, which uses VBLOC therapy to limit the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company’s VBLOC therapy is designed to block the gastrointestinal effects of the vagus nerve by replicating a vagotomy using high-frequency, low-energy electrical impulses to intermittently interrupt naturally occurring neural impulses on the vagus nerve between the brain and the digestive system.

Receive News & Ratings for EnteroMedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EnteroMedics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply